Successful interferon gamma therapy in a patient with X-linked chronic granulomatous disease, McLeod syndrome and hyper-IgE. Case report.
Recent studies have shown clinical benefit resulting from recombinant interferon gamma (rIFN-gamma) therapy in patients affected by chronic granulomatous disease (CGD), which represents an important adjunct to conventional therapy. In order to evaluate the effect of interferon gamma therapy, we investigated clinical and haematological parameters in a child with X-linked CGD, McLeod phenotype (kell negative) and hyper-IgE, before and after 8 months of therapy. Our results show no significant effect of rIFN-gamma on the respiratory burst of peripheral polymorphonuclear leukocytes. This notwithstanding, we observed improved clinical and haematological conditions. These results support the view that interferon gamma may benefit these subjects by influencing oxygen-independent antimicrobial activity or other immunological parameters.
Kantar
A
A
Department of Pediatrics, University of Ancona, Salesi Hospital.
Oggiano
N
N
Gabbianelli
R
R
Fabrizzi
G
G
Giorgi
P L
PL
D000658:Amoxicillin / Q000627:therapeutic use; D002648:Child; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D006105:Granulomatous Disease, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000187:drug effects; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008214:Lymphocytes; D008297:Male; D009580:Nitroblue Tetrazolium; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014960:X Chromosome
D009580:Nitroblue Tetrazolium; D007073:Immunoglobulin E; D000658:Amoxicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D007371:Interferon-gamma